FDA Approves Expanded Access Program For Lipella Pharma's LP-310 In Oral Lichen Planus ...
Lipella Pharmaceuticals Inc. (LIPO), a clinical-stage biotechnology company, Wednesday said that the U.S. Food and Drug ...
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral ...
The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.